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From the Editor’s Desk
POSTMORTEM CARE
Each year, death claims about 0.6% of 
the Australian population, 70% of which 
occur in the 70-plus age bracket. With such 
detached language, death seems remote 
and non-threatening. However, should we 
state that almost 130 000 young and old 
Australians will die each year, and that 
this number is set to soar in our ageing 
population, then death becomes much 
more confronting. We are reminded of 
the implicit truth embodied in Thomas 
Mann’s axiom that “A man’s dying is 
more the survivors’ affair than his own.” 
In the distant past, the spectre of death 
was wrapped into the very fabric of life, 
but this is no longer the case. Philippe Aries, 
in The hour of our death, his epic historical 
analysis of the social meaning of death, 
notes that in the 20th century “Death has 
ceased to be accepted as a natural, necessary 
phenomenon. Death is a failure, a ‘business 
lost’.”
Armed with sophisticated technology, 
pharmaceuticals, human skill and humane 
care, battles are daily waged against death, 
in operating theatres, intensive care units 
and other specialised facilities. During such 
battles, communication between doctors, 
family and friends are inclusive, intensive 
and regular, but, with death, the doctors 
suddenly disappear. The connections are 
fractured and communications abruptly 
end. The bereaved are left to cope as 
best they can.
Do our professional responsibilities 
extend beyond death? How many doctors 
conduct post-loss meetings with relatives? 
How many attend the funerals of their 
deceased patients? How many write letters 
of condolence to the bereaved family? 
Idealistic ideas? Maybe. But with the 
increasingly aloof and disengaged face 
of modern medicine, the time is long 
overdue to engage in humane gestures 
in caring for the living after a death —
postmortem care.
Martin B Van Der Weyden
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Letters
Japanese encephalitis acquired 
near Port Moresby: 
implications for residents 
and travellers to 
Papua New Guinea
Joshua P Hanson,* Carmel T Taylor,† 
Ann R Richards,‡ Ina L Smith,§ 
Craig S Boutlis¶
*Registrar, ¶ Physician, Cairns Base Hospital, 
PO Box 902, Cairns, QLD 4870; † Scientist, 
§ Research and Development Coordinator, 
Public Health Virology, Queensland Health Scientific 
Services; ‡ Public Health Nurse, Tropical Public Health 
Unit, Cairns, QLD. 
joshua_hanson@health.qld.gov.au
TO THE EDITOR: The Japanese encephali-
tis flavivirus is the most common cause of
encephali is in Asia. Death occurs in 25% of
clinical cases, and permanent neurological
deficits occur in up to 50% of survivors.1
Infection is transmitted from amplifying
hosts (primarily waterbirds and pigs) by
Culex mosquitoes. Although the virus has
been isolated in the Western Province of
Papua New Guinea,2 and clinical cases have
been described in the Western Province and
suspected in the Milne Bay region,3 to our
knowledge cases have not been reported
from around Port Moresby.
In January 2004, a 66-year-old man of
European background was evacuated to our
hospital with a 7-day history of fever and
confusion. On examination, he had general-
ised upper motor neurone signs and a Glas-
gow coma score fluctuating between 6 and
10. Computed tomography and magnetic
resonance imaging showed multiple non-
specific white-matter lesions bilaterally. An
electroencephalogram (EEG) demonstrated
diffuse slowing in the delta to theta range in
both hemispheres, with preserved response
to painful stimulation. Lumbar puncture
showed clear cerebrospinal fluid (CSF), with
a leukocyte count of 65× 106 cells/L (81%
mononuclear) (reference range [RR],
< 5 × 106 cells/L), normal erythrocyte count,
raised protein level of 0.79 g/L (RR, 150–
500 mg/L); glucose level of 4.3 mmol/L (RR,
2.8–4.0 mmol/L) and negative bacterial and
fungal cultures. The CSF was also negative
for cryptococcal antigen and by polymerase
chain reaction (PCR) testing for enterovirus
and herpes simplex, Japanese encephalitis,
Murray Valley encephalitis and Kunjin
viruses.
Serological tests were negative for syphilis
and human immunodeficiency virus infec-
tion. Paired sera from Days 2 and 19 of
admission were tested in parallel against a
panel of flaviviruses using a haemagglutina-
tion inhibition assay.4 This showed fourfold
rises in antibody titre against dengue virus
serotypes 1, 3 and 4, and Japanese encepha-
litis, Murray Valley encephalitis, Kunjin,
Alfuy and Kokobera viruses, and twofold
rises in titre against dengue virus serotype 2
and Stratford virus. Overall, these results
were diagnostic of recent flavivirus infection
but were non-specific. IgM antibody
responses to the same flaviviruses were
measured in sera and CSF using an in-house
enzyme-linked immunosorbent assay
(ELISA), with strongest reactivity demon-
strated to Japanese encephalitis virus (Box).
The patient had lived in Papua New
Guinea since 1970, predominantly on a
church-run farm at Bootless Bay, about
20 km from Port Moresby. He had not trav-
elled outside this region in the month before
his illness, and had no history of Japanese
encephalitis vaccination or of dengue fever.
The farm was situated about 150 metres
from a piggery. The patient had no direct
contact with this piggery. His accommoda-
tion was poorly screened against mosqui-
toes.
After 3 weeks of primarily supportive
intensive care, the patient was discharged to
a general ward. His neurological recovery
was slow. After 5 months, he was able to
walk with assistance and required a trache-
ostomy to protect his airway. He was judged
likely to experience permanent neurological
deficits.
The clinical, epidemiological, radiologi-
cal, EEG and serological features of this case
strongly support a diagnosis of Japanese
encephalitis. Japanese encephalitis virus is
difficult to detect in CSF by isolation or PCR
because of neutralising antibodies and the
limited duration of viraemia, which may
have accounted for the negative PCR result
in this case, despite the use of a highly
sensitive method.5
This case highlights the desirability of
further defining the epidemiology of Japa-
nese encephalitis in the Port Moresby
region, as well as reconsidering the current
recommendation to vaccinate Australians
only if they intend travelling to the Western
Province of Papua New Guinea.1
Acknowledgements: We thank Dr Jeffrey Hanna,
(Tropical Public Health Unit, Cairns, QLD) for assist-
ing in the preparation and review of this manu-
script.
1 National Health and Medical Research Council. The
Australian immunisation handbook. 8th ed. Can-
berra: Commonwealth of Australia, 2003: 175-182.
2 Johansen CA, van den Hurk AF, Ritchie SA, et al.
Isolation of Japanese encephalitis virus from mos-
quitoes (Diptera: Culicidae) collected in the West-
ern Province of Papua New Guinea, 1997-1998. Am
J Trop Med Hyg 2000; 62: 631-638.
3 Mackenzie JS. Emerging viral diseases: an Austral-
ian perspective. Emerg Infect Dis 1999; 5: 1-8.
4 Clarke DH, Casals J. Techniques for hemagglutina-
tion and hemagglutination-inhibition with arthro-
pod-borne viruses. Am J Trop Med Hyg 1958; 7:
561-573.
5 Pyke AT, Smith IL, van den Hurk AF, et al. Detection
of Australasian Flavivirus encephalitic viruses using
rapid fluorogenic TaqMan RT-PCR assays. J Virol
Methods 2004; 117: 161-167. ❏
IgM antibody levels, measured 
against a panel of flaviviruses by 
enzyme-linked immunosorbent assay 
(ELISA)
JE = Japanese encephalitis. MVE = Murray Valley 
encephalitis.
* IgM levels were measured as the P/N (positive/
negative) ratio (ratio of the absorbance of the test 
sample to the absorbance of a negative control 
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LETTERSNew recommendation on 
Japanese encephalitis 
vaccination for travellers 
to Papua New Guinea
George Rubin,* Jeanette Baird,† 
on behalf of the Australian Technical 
Advisory Group on Immunisation 
(ATAGI)
* Professor of Public Health, University of Sydney, 
NSW; † Director, Immunisation Section, Targeted 
Prevention Programs Branch, Department of Health 
and Ageing, MDP14, GPO Box 9848, Canberra, 
ACT 2601. jeanette.baird@health.gov.au
TO THE EDITOR: The Australian Technical
Advisory Group on Immunisation (ATAGI)
is responsible for maintaining and updating
the Australian immunisation handbook, on
behalf of the National Health and Medical
Research Council (NHMRC).1 At its 25th
meeting, in April 2004, ATAGI discussed
data (then unpublished) presented by Han-
son and colleagues on evidence for the
spread of Japanese encephalitis virus
beyond the Western Province of Papua New
Guinea to the Port Moresby region.2 ATAGI
believes it is probable the virus has spread to
other parts of Papua New Guinea.
The current (8th) edition of The Australian
immunisation handbook states on page 179:
“Current understanding of the ecology of
the JE [Japanese encephalitis] virus else-
where in Papua New Guinea is fragmentary
and unsubstantiated. Therefore no definitive
recommendations about JE vaccination for
travellers to other parts of Papua New
Guinea can be made at the current time.”
ATAGI agreed that the evidence provided
by Hanson and colleagues was compelling,
and sufficient to warrant expanding the
current recommendation for Japanese
encephalitis vaccination. ATAGI is propos-
ing the recommendation be changed to
include travellers staying more than one
month in all parts of Papua New Guinea, not
just those planning to stay in the Western
Province.
A public consultation process to change
this recommendation is being conducted as
part of the requirements of the NHMRC Act
1992. A public consultation paper is avail-
able from the Immunise Australia Program
website (www.immunise.health.gov.au).
Submissions close on 17 September and
can be directed to Ms Letitia Toms, Assist-
ant Director, Immunisation Section,
Department of Health and Ageing, MDP
14, GPO Box 9848, Canberra, ACT 2601
(letitia.toms@health.gov.au).
Acknowledgements: We thank Dr Jeffrey Hanna
(Tropical Public Health Unit, Cairns, QLD) and Ms
Letitia Toms (Department of Health and Ageing,
Canberra, ACT) for their assistance in the prepara-
tion and review of this manuscript.
1 National Health and Medical Research Council. The
Australian immunisation handbook. 8th edition.
Canberra: Commonwealth of Australia, 2003.
2 Hanson JP, Taylor CT, Richards AR, et al. Japanese
encephalitis acquired near Port Moresby: implica-
tions for vaccinating travellers to Papua New
Guinea [letter]. Med J Aust 2004; 181: 282. ❏
Smoking cessation and elective 
surgery: the cleanest cut
Darryl J Hodgkinson
Director, Cosmetic and Restorative Surgery Clinic, 
Double Bay Day Surgery, 20 Manning Road, 
Double Bay, Sydney, NSW 2028. 
dr_hodgkinson@bigpond.com
TO THE EDITOR: I would like to congratu-
late Peters et al on their strong stance against
elective surgery in patients who smoke.1
The plastic surgery community became
aware in the last two decades of the prob-
lems of healing in smokers. When patients
claimed that they gave up cigarette smoking
before surgery, we often found that the
serum cotinine levels on testing were ele-
vated, indicating that they had not given up
smoking.
Patients who are smokers and who
develop a healing complication, in breast
reduction, mastopexy, abdominoplasty or a
facelift, often attribute the complication to
the surgical technique rather than their own
habit. Many of these patients have gone on
to litigate successfully. Voracious plaintiff
lawyers attribute only a small amount of
blame to the patient whose smoking has, in
fact, contributed significantly to their com-
plication.
In our plastic surgery practice, we have a
non-smoking policy, and my malpractice
insurer will not cover me for patients on
whom I operate and who develop a compli-
cation associated with smoking. Hence, all
patients who are smokers who wish to have
elective surgery are referred to a smoking-
cessation program and have to have given
up smoking for at least 2 to 4 weeks before
surgery. I prefer not to operate on smokers at
all, as serum cotinine tests often confirm
that their cessation attempt has been incom-
plete.
In the United States, where patients pay
for their own health insurance, their premi-
ums are adjusted for lifestyle. In Virginia, in
the 1990s, a “Healthy Virginian policy”
existed where premiums were reduced for
non-smokers. My suggestion would be that
the Medicare levy also be either reduced for
individuals who do not smoke or increased
for those who do.
1 Peters MJ, Morgan LC, Gluch L. Smoking cessation
and elective surgery: the cleanest cut [editorial].
Med J Aust 2004; 180: 317-318. ❏
Nicholas A Tonti-Filippini
Medical Ethicist, 15 Alburnum Crescent, 
Lower Templestowe, VIC 3107. 
ntf-dsl@keypoint.com.au
TO THE EDITOR: Some time ago, I was
approached by a general practitioner who
had been trying for more than 12 months to
arrange surgery for a patient who was suffer-
ing from intermittent claudication. The indi-
cations for surgery seemed compelling. The
man was in great pain and disabled by the
condition. The vascular unit at a major
metropolitan hospital refused to operate on
him while he remained a smoker. The man
had been an alcoholic, but had managed to
beat that addiction and had been “dry” for
the entire 12 months.
With the patient’s permission, and at the
request of the GP, I contacted the surgeon.
The surgeon explained to me that his refusal
to provide elective surgery was on the
grounds that the patient smoked, which
would increase recovery time and the risk of
complications. After discussion of the ethi-
cal and legal situation, an early appointment
for surgery was arranged with the patient.
Peters and colleagues, authors of a recent
editorial on smoking cessation and elective
surgery,1 would do well to attend to the
terms of the Commonwealth Disability Dis-
crimination Act 1992. It is unlawful for a
person who provides services, or makes
facilities available, to discriminate against
another person on the grounds of the other
person’s disability.
It seems legitimate to consider the effects
of smoking on success rates as part of
deciding whether elective surgery is likely to
be safe and effective for an individual
patient. However, the editorial suggests that
patients be denied surgery, such as joint
reconstruction, as a resource-allocation
decision, even if the surgery would be in
their interests.
It is important that smoking is recognised
as an addiction. Some groups, such as the
mentally ill, are particularly prone to it. A
study by the Harvard medical school found
that people with mental illness are twice as
likely to be smokers, and nearly 45% of allMJA • Volume 181 Number 5 • 6 September 2004 283
LETTERSsmokers in the United States are people with
a “mental disorder”.2 To the extent that it is
an addiction, smoking needs to be consid-
ered as a medical condition in much the
same way as alcoholism is referred to as a
medical condition.
A doctor who did not provide a needed
treatment to a smoker on the grounds that
the patient was a smoker would be in
violation of that person’s fundamental
human right to healthcare and his or her
right not to be discriminated against because
of a disability. In fact, the doctor would be in
breach not only of the Hippocratic oath, but
of the Australian Medical Association’s Code
of Ethics 2004,3 which states “. .. refrain from
denying treatment to your patient because
of a judgement based on discrimination”.
1 Peters MJ, Morgan LC, Gluch L. Smoking cessation
and elective surgery: the cleanest cut [editorial].
Med J Aust 2004; 180: 317-318. 
2 Lasser K, Boyd JW, Woolhandler S, et al. Smoking
and mental illness: a population-based prevalence
study. JAMA 2000; 284: 2606-2610.
3 Australian Medical Association Code of Ethics 2004.
Available at: www.ama.com.au/web.nsf/doc/
WEEN-5WW598 (accessed Aug 2004). ❏
Matthew J Peters,* Lucy C Morgan,† 
Laurence Gluch‡
*Head, Department of Thoracic Medicine, †Thoracic 
Physician, ‡ Surgeon, Department of Breast and Endo-
crine Surgery, Concord Repatriation General Hospital, 
Hospital Road, Concord, NSW 2137. 
matthew.peters@cs.nsw.gov.au
IN REPLY: The rigid way in which Hodg-
kinson has addressed risk reduction in plas-
tic surgery seems reasonable, as long as
there is open disclosure and access to smok-
ing-cessation services is assured.
It is an unfortunate fact that our health-
care system cannot provide everyone with
what they want, or need, in a clinically
appropriate timeframe. Resources are finite.
In his own case example, and without con-
sidering the legal or ethical basis of his
intervention, once Tonti-Filippini arranged
for a patient at high risk of complications to
have surgery, someone else was immediately
prevented from having hospital care that
was necessary for them. If complications
developed, extending hospital stay, more
than one patient might have been adversely
affected.
Let me extend Tonti-Filippini’s case a little
and imagine that a similar patient with
peripheral vascular disease who was moved
further down the vascular surgery waiting
list as a result of the smoker’s surgery being
expedited was an ex-smoker who had taken
advice and ceased smoking to reduce risks
and improve the surgical outcome. Then, in
the period of surgical delay, the affected leg
became acutely ischaemic and amputation
(rather than vascular reconstruction) was
required. Are there not ethical implications
that follow? Reading more deeply into the
Australian Medical Association’s Code of
Ethics, one finds that we should work to
increase standards and the quality of and
access to medical services in the community,
and make available our special knowledge
and skills to assist those responsible for
allocating healthcare resources. These are
important obligations.
Most smokers are addicted, and this is a
medical problem that needs to be consist-
ently identified and addressed; the issue of
smokers with mental illness was highlighted
in the editorial. If a clinical decision is made
not to perform surgery in the context of284 MJA • Volume 181 Number 5 • 6 September 2004
LETTERScontinued smoking, it is not made because
the person is a smoker, or because they have
an addiction, but because the ongoing
smoking has major, adverse consequences
that we are unwise to ignore. The distinction
is subtle but important. ❏
Smoking and pregnancy
Jessica H Ford,* Annette J Dobson†
* Research Assistant, † Professor of Biostatistics, 
School of Population Health, University of 
Queensland, Herston Road, Herston, QLD 4006. 
A.Dobson@sph.uq.edu.au
TO THE EDITOR: Helping pregnant
women to stop smoking and not to resume
after their baby is born is a key target for
smoking prevention. Pregnancy (or trying to
become pregnant) is a time when women
are motivated to stop smoking for the sake
of the baby and they are in contact with
healthcare professionals who can help them
do so.
We have calculated the impact of smoking
during pregnancy in terms of deaths, hospi-
tal separations and costs to the healthcare
system, and estimated the extent to which
these effects could be reduced through inter-
ventions initiated by healthcare profession-
als as part of routine clinical contact.
We considered the following conditions:
pre-eclampsia (which is less common
among smokers), low birthweight (includ-
ing hospital costs for the mother and the
baby, and infant deaths), premature rupture
of membrane, spontaneous abortion,
ectopic pregnancy, placenta praevia (includ-
ing infant death), and sudden infant death
syndrome (SIDS). We used estimates of rela-
tive risks (RRs) for these conditions for
women who smoke during pregnancy (or,
for ectopic pregnancy, for women who
might become pregnant) from meta-analy-
ses.1-3 We obtained data on deaths,4 hospital
separations,5 and costs to the healthcare
system6 for 2001–02. The prevalence of
smoking among pregnant women of all ages
in New South Wales since 1994 has been in
the range 17% to 22%.7 The prevalence of
smoking among all women of child-bearing
age in 2001 was about 28%.8 From these
data, we calculated attributable fractions1,2,9
for average values (using point estimates for
RRs and 20% for prevalence of smoking in
pregnancy) and extreme values (using the
95% confidence limits for RRs and 17% and
22% for smoking prevalence).
In summary, the average number of
adverse events attributable to smoking each
year in Australia are: infant deaths, 78
(extreme values, 66–87); hospital separa-
tions, 6890 (extreme values, 4130–9450);
costs to the healthcare system, $23 million
(extreme values, $16–$29 million).
A Cochrane review of behavioural (not
pharmacological) interventions for stopping
smoking in pregnancy showed an absolute
reduction of 6% (95% CI, 4%–8%).10 Thus,
if the prevalence of smoking during preg-
nancy were reduced from 20% to 14%, we
calculate that there would be 20 fewer infant
deaths, 1600 fewer hospital separations, and
a saving of $5 million to the Australian
healthcare system per year. (Details of the
calculations can be obtained from the
authors.)
These gains could be realised by increas-
ing community awareness of the risks of
smoking in pregnancy and helping healthMJA • Volume 181 Number 5 • 6 September 2004 285
LETTERSprofessionals to use smoking prevention
strategies in their routine encounters with
pregnant women.
Acknowledgement: This work was supported by a
grant from the Medical Benefits Fund of Australia.
1 English DR, Holman CDJ, Milne E, et al. The quanti-
fication of drug caused morbidity and mortality in
Australia. 1995 edition. Canberra: Commonwealth
Department of Human Services and Health, 1995.
2 Ridolfo B, Stevenson C. The quantification of drug-
caused mortality and morbidity in Australia, 1998.
Canberra: Australian Institute of Health and Wel-
fare, 2001. (AIHW Catalogue No. PHE 29; Drug
Statistics Series No.7.)
3 Castles A, Adams EK, Melvin CL, et al. Effects of
smoking during pregnancy: five meta analyses. Am
J Prev Med 1999; 16: 208-215.
4 Australian Bureau of Statistics. Causes of death,
Australia 2002. Canberra: ABS, 2002. (ABS Cata-
logue No. 3303.0.)
5 Australian Institute of Health and Welfare Inter-
active National Hospital Morbidity Data 2001–02.
Canberra: Australian Institute of Health and Wel-
fare. Available at: www.aihw.gov.au/cognos/cgi-bin/
ppdscgi.exe?DC=Q&E=/AHS/principaldiagnosis
0102 (accessed Jan 2004).
6 National Hospital Cost Data Collection. Round 6
(2001–02). Australian refined diagnosis related
groups 4.2. Cost weights. Canberra: Common-
wealth Department of Health and Ageing, 2002.
Available at: www.health.gov.au/casemix/costing/
graph_table/round6/Publ ic_National_Cost_
Weights_Round_6_estim.xls (accessed Apr 2004).
7 Centre for Epidemiology and Research, NSW
Department of Health. New South Wales mothers
and babies, 2001. NSW Public Health Bull 2002; 13
Suppl S-4: 1-124.
8 Australian Bureau of Statistics. National health sur-
vey 2001. Canberra: ABS, 2002 (ABS Catalogue No.
4364.0.)
9 Adams EK, Melvin CL. Costs of maternal conditions
attributable to smoking during pregnancy. Am J
Prev Med 1998; 15: 212-219.
10 Lumley J, Oliver S, Waters E. Interventions for
promoting smoking cessation during pregnancy
(Cochrane Review). In: The Cochrane Library, Issue
2, 2004. Chichester, UK: John Wiley & Sons, Ltd. ❏
Androgen deficiency and 
replacement therapy in men
Adam P Morton*
* Endocrinologist, Mater Hospital, South Brisbane, 
QLD 4101. Amorton@mater.org.au
TO THE EDITOR: I appreciated the recent
comprehensive review of androgen defi-
ciency and replacement therapy in men by
Handelsman and Zajac.1 I ask their opinion
of the importance of obstructive sleep
apnoea as a cause of secondary hypogonad-
ism, and also of the safety of androgen
replacement in men with hypogonadism
who have obstructive sleep apnoea but are
intolerant of continuous positive airway
pressure (CPAP) treatment.
In my practice, obstructive sleep apnoea
is one of the most common associations, if
not indeed causes, of hypogonadotropic
hypogonadism. Several studies have
shown that obstructive sleep apnoea is
associated with secondary hypogonadism,
which is partly or completely reversed by
both CPAP treatment and uvulopalato-
pharyngoplasty.2-4 Secondary hypogonad-
ism is also a feature of several conditions
in which there is a high prevalence of
obstructive sleep apnoea, including
chronic spinal cord injury and cardiac
failure. Of concern, studies have shown
that androgen replacement may precipitate
or worsen obstructive sleep apnoea.5,6
Similarly, a study of women with endo-
genous androgen excess caused by poly-
cystic ovary syndrome found they were 30
times more likely to suffer from sleep-
disordered breathing than control
women.7 A single case report describes
resolution of obstructive sleep apnoea in a
non-obese woman after removal of a
benign testosterone-producing ovarian
tumour.8
Thus, I would value Handelsman and
Zajac’s comments as to whether they con-
sider obstructive sleep apnoea to be an
important cause of secondary hypogonad-
ism, and whether symptoms of this condi-
tion should be sought before initiating
androgen replacement therapy.
1 Handelsman DJ, Zajac JD. Androgen deficiency
and replacement therapy in men. Med J Aust
2004; 180: 529-535.
2 Luboshitzky R, Lavie L, Shen-Orr Z, Lavie P. Pitui-
tary-gonadal function in men with obstructive
sleep apnea. The effect of continuous positive
airways pressure treatment. Neuroendocrinol Lett
2003; 24: 463-467.
3 Grunstein RR, Handelsman DJ, Lawrence SJ, et al.
Neuroendocrine dysfunction in sleep apnea:
reversal by continuous positive airways pressure
therapy. J Clin Endocrinol Metab 1989; 68: 352-
358.
4 Santamaria JD, Prior JC, Fleetham JA. Reversible
reproductive dysfunction in men with obstructive
sleep apnoea. Clin Endocrinol 1988; 28: 461-470.
5 Liu PY, Yee B, Wishart SM, et al. The short-term
effects of high-dose testosterone on sleep,
breathing, and function in older men. J Clin
Endocrinol Metab 2003; 88: 3605-3613.
6 Matsumoto AM, Sandblom RE, Schoene RB, et al.
Testosterone replacement in hypogonadal men:
effects on obstructive sleep apnoea, respiratory
drives, and sleep. Clin Endocrinol 1985; 22: 713-
721.
7 Vgontzas AN, Legro RS, Bixler EO, et al.  Poly-
cystic ovary syndrome is associated with obstruc-
tive sleep apnea and daytime sleepiness: role of
insulin resistance. J Clin Endocrinol Metab 2001;
86: 517-520.
8 Dexter DD, Dovre EJ. Obstructive sleep apnea
due to endogenous testosterone production in a
woman. Mayo Clin Proc 1998; 73: 246-248. ❏
David J Handelsman,* Jeffrey D Zajac†
* Director, ANZAC Research Institute, Concord 
Hospital, Hospital Road, Concord, NSW 2139; 
† Head, Department of Medicine, Austin Hospital, 
Melbourne, VIC. djh@anzac.edu.au
IN REPLY: We thank Morton for his
thoughtful comment that, in addition to
monitoring for obstructive sleep apnoea pre-
cipitated by testosterone therapy, it may be
worthwhile screening for this condition
before starting treatment. Symptoms to be
sought include daytime sleepiness and part-
ner reports of loud and irregular snoring,
especially among overweight men with large
collar size.
Obstructive sleep apnoea rises steeply in
prevalence with age and causes mild hypo-
gonadotropic hypogonadism, which is recti-
fied by effective continuous positive airway
pressure (CPAP) treatment.1 Obesity,
depression, cardiovascular disease and other
conditions that become more common with
age have similar effects. Together, they con-
tribute to the lower blood testosterone levels
found in unselected older men, in whom
testosterone remains an unproven treat-
ment.2 This condition differs from classical
hypogonadotropic hypogonadism caused by
hypothalamic or pituitary disorders, which
routinely requires lifelong testosterone
replacement, and (occurring in a younger
population) is rarely associated with
obstructive sleep apnoea.
The prevalence of obstructive sleep
apnoea precipitated by testosterone treat-
ment remains unclear. A case precipitated
by injectable testosterone has been
reported,3 while testosterone has potential
adverse effects on sleep in older men.4 Clin-
ical experience suggests that, among
younger hypogonadal men, obstructive
sleep apnoea is a rare idiosyncratic reaction
to testosterone, which, like polycythaemia,
may be particularly related to supraphysio-
logical blood testosterone levels. However,
the prevalence may be higher among older
men. Hence, we agree that pretreatment
screening is wise (rather than proven) for
older men starting testosterone treatment,
but is not routinely necessary for young men
with classical hypogonadism.
1 Grunstein RR, Handelsman DJ, Lawrence SJ, et al.
Hypothalamic dysfunction in sleep apnea: reversal
by nasal continuous positive airways pressure. J Clin
Endocrinol Metab 1989; 68: 352-358.
2 Liverman CT, Blazer DG, editors. Testosterone and
aging: clinical research directions. Washington, DC:
Institute of Medicine, The National Academies
Press, 2004.
3 Sandblom RE, Matsumoto AM, Scoene RB, et al.
Obstructive sleep apnea induced by testosterone
administration. N Engl J Med 1983; 308: 508-510.286 MJA • Volume 181 Number 5 • 6 September 2004
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effects of high dose testosterone on sleep, breath-
ing and function in older men. J Clin Endocrinol
Metab 2003; 88: 3605-3613. ❏
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TO THE EDITOR: The article by Seeman
and Eisman on treatment of osteoporosis1
not only neglects the pathogenesis and pre-
vention of this condition, but also fails to
appreciate the profound differences between
the three main types of fragility fracture
(peripheral non-hip, hip and spine).
To say that adults lose bone with age
because the “volume of bone resorbed is
greater than the volume replaced” is a spec-
tacular but common tautology which simply
describes what would be expected from an
external negative calcium balance. The com-
mon postmenopausal bone loss can gener-
ally be accounted for by the rise in calcium
requirement due to a fall in calcium absorp-
tion and rise in obligatory calcium excre-
tion.2-4 This can be corrected with
hormones or compensated for with a cal-
cium supplement, which is known to sup-
press bone resorption.5 In 20 trials of
calcium therapy completed up to 1997, the
loss of bone in 855 postmenopausal women
treated with calcium was 0.3% per annum,
compared with 1.0% per annum in 635
untreated control women (P < 0.001).6
In older women, this relative calcium
deficiency is complicated by a decline in
vitamin D status caused by reduced expo-
sure to sunlight and progressive thinning of
the skin. It has been known for 30 years that
vitamin D deficiency is common in patients
with hip fracture,7 for 20 years that this was
also true in Australia,8 and for 12 years that
vitamin D with calcium can reduce the hip
fracture rate by 43% in 18 months in
women in residential care.9
When it comes to established osteoporo-
sis (the combination of low bone density
with fracture), treatment needs to distin-
guish between the three main types of frac-
ture referred to above. In hip fractures,
surely the first priority must be to give
adequate vitamin D and calcium. Most non-
hip peripheral fractures occur in women
with bone densities in the normal range,10
so the need for treatment is debatable unless
bone turnover is very high.
Vertebral fractures are a different matter.
Unlike peripheral fractures, they do not
“heal” in the usual sense — the deformity
remains and often causes local pain and
mechanical dysfunction. The recurrence rate
is very high, because all the vertebrae have
much the same bone density, and the osteo-
porotic collapse of one indicates that the
others are ready to follow. This condition is
notoriously difficult to manage and should
almost be regarded as a medical emergency
that requires full investigation — not least to
exclude myeloma — and rapid, effective
treatment. It is in the secondary prevention
of these fractures that the remedies advo-
cated by Seeman and Eisman probably have
their main role and are most cost-effective.
In fact, although the authors place great
emphasis on prevalent fracture as a risk
factor for further fracture, the reference they
quote deals with prevalent vertebral frac-
ture, not with prevalent non-hip peripheral
fracture, where the evidence of benefit from
bisphosphonates and raloxifene is very
much weaker.
We are arguing for much greater empha-
sis on the prevention of osteoporosis with
adequate calcium after the menopause and
adequate vitamin D in the elderly, and the
use of appropriate investigation and selec-
tive treatment in the management of the
condition when it is established.
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IN REPLY: Our article concerned a discus-
sion of evidence-based treatment for the
prevention of osteoporotic fractures. Preven-
tion of osteoporosis per se is important, but
the approaches chosen must be evidence-
based. Calcium supplementation may
diminish, but not abolish, bone loss by
reducing remodelling rate.1 Any association
of a lifelong diet high in calcium appears to
be with peak bone mass, not rates of bone
loss,2 and may be attributable to differences
in protein intake or physical activity. Despite
opinion, meta-analysis of prospective, ran-
domised, double-blind, placebo-controlled
studies does not support a role for calcium
supplementation in reducing fractures.3
Later rather than earlier intervention
avoids needless exposure to treatment for
large numbers of individuals at low absolute
risk of fracture (ie, those who are unlikely to
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sustain a fracture even without treatment).4
Vitamin D is of course indicated in vitamin
D deficiency. However, there is no evidence
for anti-fracture efficacy of vitamin D in
ambulant community dwellers.5
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TO THE EDITOR: Byard’s succinct disser-
tation on the Clark case1 omits one crucial
aspect in redressing this miscarriage of
justice. Without the vigorous and persist-
ent efforts of a vocal and well directed
support group, which included Mrs Clark’s
legal team, their scientific and medical
advisors, the Law Society of England, and
her family, she would still be serving a life
sentence in jail.
An Australian example of the effective-
ness of such a support group in combating
injustice is afforded by the Lindy Chamber-
lain case.2
Historically, Sir Arthur Conan Doyle
spearheaded the efforts — sustained over
nearly 20 years — to exonerate Oscar
Slater,3 an unfortunate German–Jewish
immigrant to Glasgow who was con-
demned to death after a conviction for
murder based largely on identification evi-
dence given by one of the probable perpe-
trators. Slater was granted a reprieve from
the death sentence at the last moment, only
to serve some 17 years in a grim Scottish
penitentiary. Less fortunate was Timothy
Evans,4 who was convicted and hanged for
murdering his wife and daughter on the
evidence of one of London’s infamous mass
murderers, John Christie. Evans was even-
tually pardoned — unfortunately, too late
to save his life — largely thanks to a very
active support group headed by the jour-
nalist Ludovic Kennedy.
In contrast, those who lack such a sup-
port group are exemplified by Ziggy Pohl,5
who was convicted, despite rather than
because of the evidence, of killing his wife
in Queanbeyan, NSW. He served more than
a decade in prison, only to have the true
perpetrator confess after Pohl was released
on parole.
Byard highlights evidentiary shortcom-
ings in one recent English case. How many
other people have suffered the ignominy,
distress and dire consequences of unjust
convictions because they lacked the sup-
port of an individual or a group prepared
to question the propriety of the conviction
process?
1 Byard R. Unexpected infant death: lessons from the
Sally Clark case. Med J Aust 2004; 181: 52-54.
2 Royal Commission of Inquiry into the Chamberlain
Convictions. Report by the Commissioner the Hon.
Mr Justice T R Morling. Darwin: NT Government
Printer, 1987.
3 Mortimer J, editor. Famous trials. London: Penguin,
1984: 78-132.
4 Kennedy L. 10 Rillington Place. London: HarperCol-
lins, 1995.
5 Report of the inquiry held under s 475 of the Crimes
Act 1900 into the conviction of Johann Ernst Zieg-
fried Pohl at the Central Criminal Court on 2nd
November 1973 (McInerney J). Sydney: NSW Gov-
ernment Printer, 1992. ❏
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